Document is current
Any future updates will be listed below
-
Authors
Takahashi, Naoto https://orcid.org/0000-0002-6758-3787
Cortes, Jorge E.
Sakaida, Emiko
Ishizawa, Kenichi
Ono, Takaaki
Doki, Noriko
Matsumura, Itaru
García-Gutiérrez, Valentín
Rosti, Gianantonio
Ono, Chiho
Ohkura, Masayuki
Tanetsugu, Yusuke
Viqueira, Andrea
Brümmendorf, Tim H.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02130557 at ClinicalTrials.govnct03128411 at ClinicalTrials.govDocuments that mention this clinical trial
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis
https://doi.org/10.1007/s12185-022-03314-y
nct00574873 at ClinicalTrials.govDocuments that mention this clinical trial
Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study
https://doi.org/10.1007/s12185-022-03435-4
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis
https://doi.org/10.1007/s12185-022-03314-y
nct00261846 at ClinicalTrials.govDocuments that mention this clinical trial
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis
https://doi.org/10.1007/s12185-022-03314-y
nct01903733 at ClinicalTrials.govDocuments that mention this clinical trial
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis
https://doi.org/10.1007/s12185-022-03314-y
nct00811070 at ClinicalTrials.govDocuments that mention this clinical trial
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis
https://doi.org/10.1007/s12185-022-03314-y
nct02228382 at ClinicalTrials.govDocuments that mention this clinical trial
Induced pluripotent stem cell–based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients
https://doi.org/10.1136/bmjopen-2019-033131
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis
https://doi.org/10.1007/s12185-022-03314-y
Documents that mention this clinical trial
Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis
https://doi.org/10.1007/s12185-022-03314-y
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 5 October 2021
Revised: 10 February 2022
Accepted: 14 February 2022
First Online: 2 March 2022
Declarations
:
: Naoto Takahashi reports research funding from Novartis, Otsuka, Pfizer, Asahi Kasei, Astellas Pharma, and Ono Pharmaceutical, and speakers bureau with Novartis, Otsuka, Pfizer, and Bristol Myers Squibb. Jorge E. Cortes reports consultancy with Amphivena Therapeutics, Astellas Pharma, Bio-Path Holdings Inc, BiolineRx, Bristol Myers Squibb, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Pfizer, and Takeda, and research funding from Astellas Pharma, Bristol Myers Squibb, Daiichi Sankyo, Immunogen, Jazz Pharmaceuticals, Merus, Novartis, Pfizer, Sun Pharma, Takeda, Tolero Pharmaceuticals, and Trovagene. Emiko Sakaida reports research funding from Bristol Myers Squibb, Chugai, Kyowa Kirin, Ono, and Pfizer. Kenichi Ishizawa reports research funding from Novartis, AbbVie, Bayer, SymBio, Otsuka, Pfizer, Takeda, and Kyowa Kirin, and speakers bureau with Takeda, Celgene, Ono, Novartis, Chugai, and Eisai. Takaaki Ono reports honoraria from Bristol Myers Squibb, Celgene, Merck Sharp & Dohme, Novartis, Ono, Otsuka, Pfizer, and Takeda, and research funding from Celgene, Chugai, Kyowa Hakko Kirin, Merck Sharp & Dohme, Ono, and Pfizer. Itaru Matsumura reports speakers bureau with Amgen Astellas BioPharma K.K., Astellas Pharma, Bristol Myers Squibb, Daiichi Sankyo, Janssen Pharmaceutical K.K., Novartis Pharma K.K., Otsuka Pharmaceutical, Pfizer Japan Inc, and research funding from AbbVie G.K., Asahi Kasei Pharma, Chugai Pharmaceutical, Eisai, Japan Blood Products Organization, Kyowa Kirin, Mitsubishi Tanabe Pharma, MSD K.K., Nippon Shinyaku, Ono Pharmaceutical, Shionogi, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, and Takeda.. Valentín García-Gutiérrez reports consultancy with Bristol Myers Squibb, Incyte, Novartis, and Pfizer, and research funding from Pfizer. Gianantonio Rosti reports research funding from Pfizer, and speakers bureau with Bristol Myers Squibb, Incyte, Novartis, and Pfizer. Chiho Ono reports employment by and stock options with Pfizer. Masayuki Ohkura and Yusuke Tanetsugu report employment by Pfizer R&D Japan G.K. Andrea Viqueira reports employment by and stock ownership in Pfizer. Tim H. Brümmendorf reports consultancy with Janssen, Merck, Novartis, and Pfizer, research funding from Novartis and Pfizer, and honoraria from Novartis and Pfizer.
